AU2003258662A1 - Use of 4-amino-quinazolines as anti cancer agents - Google Patents

Use of 4-amino-quinazolines as anti cancer agents

Info

Publication number: AU2003258662A1
Authority: AU; Australia
Prior art keywords: quinazolines; amino; cancer agents; anti cancer; agents
Prior art date: 2002-10-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2003258662A

Inventor

Gerhard Barnickel

Hans-Michael Eggenweiler

Volker Eiermann

Rolf Gericke

Wilfried Rautenberg

Burkhard Scharm

Christian Sirrenberg

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merck Patent GmbH

Original Assignee

Merck Patent GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-02

Filing date

2003-08-25

Publication date

2004-04-23

2003-08-25 Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH

2004-04-23 Publication of AU2003258662A1 publication Critical patent/AU2003258662A1/en

Status Abandoned legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AU2003258662A 2002-10-02 2003-08-25 Use of 4-amino-quinazolines as anti cancer agents Abandoned AU2003258662A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP02022152		2002-10-02
EP02022152.9		2002-10-02
PCT/EP2003/009391 WO2004030671A2 (en)	2002-10-02	2003-08-25	Use of 4-amino-quinazolines as anti cancer agents

Publications (1)

Publication Number	Publication Date
AU2003258662A1 true AU2003258662A1 (en)	2004-04-23

Family

ID=32049972

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2003258662A Abandoned AU2003258662A1 (en)	2002-10-02	2003-08-25	Use of 4-amino-quinazolines as anti cancer agents

Country Status (2)

Country	Link
AU (1)	AU2003258662A1 (en)
WO (1)	WO2004030671A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2005281704A1 (en)	2004-09-06	2006-03-16	Nycomed Gmbh	Novel pyrazolopyrimidines
KR101270122B1 (en)	2007-11-01	2013-05-31	어큐셀라 인코포레이티드	Amine derivative compounds for treating ophthalmic diseases and disorders
EP2241565A1 (en)	2009-01-15	2010-10-20	Universität Leipzig	Aurora kinase inhibitors compounds
ES2900504T3 (en)	2009-09-03	2022-03-17	Bristol Myers Squibb Co	Quinazolines as inhibitors of potassium ion channels
WO2011029054A1 (en)	2009-09-04	2011-03-10	The Regents Of The University Of Michigan	Compositions and methods for treatment of leukemia
US9951029B2 (en)	2013-08-09	2018-04-24	Vichem Chemie Kutató Kft.	Styryl quinazoline derivatives as pharmaceutically active agents
US10246464B2 (en)	2014-09-09	2019-04-02	The Regents Of The University Of Michigan	Thienopyrimidine and thienopyridine compounds and methods of use thereof
TWI703150B (en)	2015-06-04	2020-09-01	美商庫拉腫瘤技術股份有限公司	Methods and compositions for inhibiting the interaction of menin and mll proteins
HK1246593A1 (en)	2015-06-04	2018-09-14	Kura Oncology, Inc.	Methods and compositions for inhibiting the interaction of menin with mll proteins
WO2017161002A1 (en)	2016-03-16	2017-09-21	Kura Oncology, Inc.	Bridged bicyclic inhibitors of menin-mll and methods of use
WO2017161028A1 (en)	2016-03-16	2017-09-21	Kura Oncology, Inc.	Substituted inhibitors of menin-mll and methods of use
US11944627B2 (en)	2017-03-24	2024-04-02	Kura Oncology, Inc.	Methods for treating hematological malignancies and Ewing's sarcoma
WO2018226976A1 (en)	2017-06-08	2018-12-13	Kura Oncology, Inc.	Methods and compositions for inhibiting the interaction of menin with mll proteins
EP3684361A4 (en)	2017-09-20	2021-09-08	Kura Oncology, Inc.	MENINE-MLL SUBSTITUTE INHIBITORS AND METHODS OF USE
KR102490434B1 (en) *	2020-09-25	2023-01-19	한양대학교 에리카산학협력단	Novel quinazoline derivatives having FLT3-inhibitory activity and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6046206A (en) *	1995-06-07	2000-04-04	Cell Pathways, Inc.	Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US20020025968A1 (en) *	1998-04-15	2002-02-28	Rifat Pamukcu	Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives
HUP0201215A2 (en) *	1998-12-02	2002-08-28	Pfizer Prod Inc	Methods and compositions for restoring conformational stability of a protein of the p53 family
EP1192270A2 (en) *	1999-06-14	2002-04-03	Novo Nordisk A/S	FVIIa/TF ACTIVITY INHIBITING COMPOUNDS
EP1277738B1 (en) *	2000-04-27	2011-03-30	Astellas Pharma Inc.	Condensed heteroaryl derivatives

2003
- 2003-08-25 WO PCT/EP2003/009391 patent/WO2004030671A2/en not_active Ceased
- 2003-08-25 AU AU2003258662A patent/AU2003258662A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2004030671A3 (en)	2004-06-10
WO2004030671A2 (en)	2004-04-15

Publication	Publication Date	Title
AU2003255482A1 (en)	2004-04-23	Use of 4 amino-quinazolines as anti cancer agents
WO2003073826A8 (en)	2005-04-28	Novel compositions and methods for cancer
AU2003213144A1 (en)	2003-09-09	Alkylating agent combinations in the treatment of cancer
AUPS054702A0 (en)	2002-03-07	Cancer therapy
AU2003286263A1 (en)	2004-06-23	Complexes of receptors
AU2003304507A1 (en)	2005-05-05	Anti-coronavirus agent
AU2003212634A1 (en)	2003-09-22	Compounds useful in the treatment of cancer
AU2003220968A1 (en)	2003-10-13	Anti-inflammatory agent
AU2003258662A1 (en)	2004-04-23	Use of 4-amino-quinazolines as anti cancer agents
AU2003292263A1 (en)	2004-08-10	Use of substituted 2-phenylbenzimidazoles as medicaments
AU2003227489A1 (en)	2004-11-04	Skin protecting compositions
AU2003219160A1 (en)	2004-09-30	Methods and compositions for the treatment of cancer
AU2003275505A1 (en)	2004-04-23	Electowinning of metals
AU2003223538A1 (en)	2003-10-27	Methods for the treatment of cancer
AU2003224000A1 (en)	2003-10-08	Compounds useful as photodynamic therapeutic agents
AU2003215150A1 (en)	2003-09-02	Therapeutic compounds
AU2003290818A1 (en)	2004-06-03	Topoisomerase-targeting agents
AU2003289207A1 (en)	2004-06-30	Anti-inflammatory agent
AU2003296242A1 (en)	2004-06-18	Thia-epothilone derivatives for the treatment of cancer
AU2003231803A1 (en)	2003-12-02	Treatment of cancer with mefloquire
AU2003283339A1 (en)	2004-06-07	Cancer therapy determination
AU2003207181A1 (en)	2003-09-02	Microorganism-trapping agent
AU2003232189A1 (en)	2003-10-08	Antifouling agent
AU2004281077A1 (en)	2005-04-28	Methods and agents for the treatment of cancer
AU2003240174A1 (en)	2003-12-22	Compositions for the treatment of edematous-firbrosclerotic panniculopathy

Legal Events

Date	Code	Title	Description
2005-06-16	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase